CL2021003374A1 - Inhibidores de glicolato oxidasa para el tratamiento de enfermedades - Google Patents
Inhibidores de glicolato oxidasa para el tratamiento de enfermedadesInfo
- Publication number
- CL2021003374A1 CL2021003374A1 CL2021003374A CL2021003374A CL2021003374A1 CL 2021003374 A1 CL2021003374 A1 CL 2021003374A1 CL 2021003374 A CL2021003374 A CL 2021003374A CL 2021003374 A CL2021003374 A CL 2021003374A CL 2021003374 A1 CL2021003374 A1 CL 2021003374A1
- Authority
- CL
- Chile
- Prior art keywords
- diseases
- compounds
- glycolate oxidase
- treatment
- oxidase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
La presente invención se refiere a compuestos, métodos para elaborar tales compuestos, composiciones farmacéuticas y medicamentos que contienen tales compuestos, y métodos para usar tales compuestos para tratar o prevenir enfermedades o trastornos asociados con un defecto en el metabolismo de glioxilato, por ejemplo una enfermedad o trastorno asociado con la enzima glicolato oxidasa (GO) o alteraciones en el metabolismo de oxalato. Tales enfermedades o trastornos incluyen, por ejemplo, trastornos del metabolismo de glioxilato, que incluyen hiperoxaluria primaria, que están asociados con la producción de cantidades excesivas de oxalato.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962863786P | 2019-06-19 | 2019-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021003374A1 true CL2021003374A1 (es) | 2022-09-23 |
Family
ID=74040914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021003374A CL2021003374A1 (es) | 2019-06-19 | 2021-12-16 | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades |
Country Status (14)
Country | Link |
---|---|
US (1) | US20230088214A1 (es) |
EP (1) | EP3986863A4 (es) |
JP (1) | JP2022536969A (es) |
KR (1) | KR20220048489A (es) |
CN (1) | CN114258390A (es) |
AU (1) | AU2020298238A1 (es) |
BR (1) | BR112021025781A2 (es) |
CA (1) | CA3143334A1 (es) |
CL (1) | CL2021003374A1 (es) |
IL (1) | IL288920A (es) |
MX (1) | MX2021015874A (es) |
PE (1) | PE20220901A1 (es) |
TW (1) | TW202115013A (es) |
WO (1) | WO2020257487A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202340155A (zh) * | 2017-12-29 | 2023-10-16 | 美商拜奧馬林製藥公司 | 用於疾病治療之乙醇酸酯氧化酶抑制劑 |
KR20210041564A (ko) | 2018-07-06 | 2021-04-15 | 오판 바이오테크 인코포레이티드 | 트리아졸 글리콜레이트 옥시다아제 억제제 |
EP4017490A4 (en) | 2019-08-22 | 2023-11-22 | Oxalurx, Inc. | COMPOUNDS AND METHODS OF TREATING OXALATE-RELATED DISEASES |
CA3155577A1 (en) | 2019-11-01 | 2021-05-06 | GyanRx Sciences, Inc. | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors |
EP4043018A1 (en) * | 2021-02-10 | 2022-08-17 | Charité - Universitätsmedizin Berlin | Composition and method for reducing oxalate levels in patients receiving maintenance dialysis |
CN113429238A (zh) * | 2021-07-23 | 2021-09-24 | 甘肃省农业科学院旱地农业研究所 | 一种有机肥及其制备方法 |
CN115246842A (zh) * | 2022-06-15 | 2022-10-28 | 深圳湾实验室 | 一类靶向去泛素化酶usp25和usp28的小分子抑制剂 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4537902A (en) * | 1979-06-11 | 1985-08-27 | Merck & Co., Inc. | 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase |
US6355638B1 (en) * | 1999-11-25 | 2002-03-12 | Merck Sharp & Dohme Ltd. | Pyrazolo[1,5-d][1,2,4] triazines for enhancing cognition |
GB0028583D0 (en) * | 2000-11-23 | 2001-01-10 | Merck Sharp & Dohme | Therapeutic compounds |
US6962936B2 (en) * | 2001-04-27 | 2005-11-08 | Vertex Pharmaceuticals Incorporated | Triazole-derived kinase inhibitors and uses thereof |
JP4075357B2 (ja) * | 2001-11-15 | 2008-04-16 | 宇部興産株式会社 | 4,5−ジ置換−1,2,3−トリアゾール及びその製造法 |
TW201418242A (zh) * | 2012-10-26 | 2014-05-16 | Du Pont | 作為除草劑之經取代的三唑 |
US8987471B2 (en) * | 2013-02-14 | 2015-03-24 | Allergan, Inc. | Substituted dihydropyrazoles as sphingosine receptor modulators |
US20200262794A1 (en) * | 2015-12-07 | 2020-08-20 | Wake Forest University Health Sciences | Glycolate oxidase inhibitors and methods of use for the treatment of kidney stones |
-
2020
- 2020-06-18 BR BR112021025781A patent/BR112021025781A2/pt unknown
- 2020-06-18 CA CA3143334A patent/CA3143334A1/en active Pending
- 2020-06-18 AU AU2020298238A patent/AU2020298238A1/en active Pending
- 2020-06-18 WO PCT/US2020/038480 patent/WO2020257487A1/en active Application Filing
- 2020-06-18 EP EP20827629.5A patent/EP3986863A4/en active Pending
- 2020-06-18 JP JP2021575417A patent/JP2022536969A/ja active Pending
- 2020-06-18 KR KR1020227000835A patent/KR20220048489A/ko active Search and Examination
- 2020-06-18 MX MX2021015874A patent/MX2021015874A/es unknown
- 2020-06-18 US US17/619,818 patent/US20230088214A1/en not_active Abandoned
- 2020-06-18 TW TW109120653A patent/TW202115013A/zh unknown
- 2020-06-18 PE PE2021002115A patent/PE20220901A1/es unknown
- 2020-06-18 CN CN202080058790.2A patent/CN114258390A/zh active Pending
-
2021
- 2021-12-12 IL IL288920A patent/IL288920A/en unknown
- 2021-12-16 CL CL2021003374A patent/CL2021003374A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3986863A1 (en) | 2022-04-27 |
US20230088214A1 (en) | 2023-03-23 |
TW202115013A (zh) | 2021-04-16 |
CN114258390A (zh) | 2022-03-29 |
AU2020298238A1 (en) | 2022-02-10 |
KR20220048489A (ko) | 2022-04-19 |
IL288920A (en) | 2022-02-01 |
BR112021025781A2 (pt) | 2022-03-03 |
JP2022536969A (ja) | 2022-08-22 |
MX2021015874A (es) | 2022-02-03 |
WO2020257487A1 (en) | 2020-12-24 |
PE20220901A1 (es) | 2022-05-30 |
CA3143334A1 (en) | 2020-12-24 |
EP3986863A4 (en) | 2023-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021003374A1 (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades | |
CL2020001742A1 (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades | |
CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
DOP2021000079A (es) | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 | |
CL2023002682A1 (es) | Uso de inhibidores de ehmt2 para tratar trastornos sanguíneos | |
SV2018005742A (es) | Inhibidores de mcl-1 macrocíclicos para tratar el cáncer | |
CL2020002401A1 (es) | Composiciones de arni de 17 b-hidroxiesteroide deshidrogenasas tipo 13 (hsd17b13) y métodos de uso de las mismas. | |
BR112017013599A2 (pt) | composição farmacêutica, e, método para prevenir, tratar ou melhorar um ou mais sintomas de um tumor maligno associado à mutação de kras. | |
BR112018005223A2 (pt) | compostos e métodos para modular a expressão de angiotensinogênio | |
CL2021002877A1 (es) | Inhibidores del gen kcnt1, composiciones y usos para trastornos neurológicos | |
CL2021002876A1 (es) | Inhibidores del gen kcnt1, composiciones y usos para trastornos neurológicos | |
CR20200224A (es) | Composiciones y métodos de tratamiento de la insuficiencia cardiaca con fracción de eyección reducida con dapagliflozina | |
CO2022017072A2 (es) | Imidazopiridazinas como moduladores de il-17 | |
CO2021002691A2 (es) | Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1) | |
BR112017010599A2 (pt) | análogos de ureia ligada substituída como moduladores sirtuin | |
CL2022001178A1 (es) | Ligandos de la pseudoquinasa tyk2 | |
BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
UY39150A (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
BR112023001861A2 (pt) | Composições e métodos para tratamento de doenças e distúrbios | |
CL2023000943A1 (es) | Formas cristalinas de un compuesto farmacéutico. | |
CO2018013828A2 (es) | Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato | |
BR112022007010A2 (pt) | Terapia gênica para doença de alzheimer | |
CO2023005942A2 (es) | Composiciones farmacéuticas de un inhibidor de cinasa | |
CL2020003143A1 (es) | Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria | |
EA201992178A1 (ru) | Фармацевтические композиции с высоким содержанием лекарственного средства из среднецепочечных триглицеридов и способы, связанные c ними |